Holdings data in Kamhada shares
According to FUNDER website data,
78 mutual funds hold Kamahada shares in the amount of NIS 33.64 million
Funds that hold significant holdings in the stock – for the full list of holdings
The following is a change in the holdings of mutual funds in Kamahada shares according to FUNDER-MVF data.
• Kamahda entered the US plasma collection market through the acquisition of an active and FDA approved plasma collection center, this acquisition promotes the company’s strategy to become a unique and unique plasma products company focused on expanding its antibody preparation portfolio.
• The Israeli Ministry of Health has begun treatment of hospitalized corona patients using Kamahada’s plasma-based experimental antibody preparation (IgG), which is given mainly as part of a multicenter clinical trial led by the ministry; The current supply volume of the drug is expected to be sufficient to treat about 500 patients.
• KamHada continues to expand its business activities as demonstrated in the expansion of its portfolio of biosimilar products for distribution in Israel, in addition the company continues to work to identify opportunities for business development, and plans to utilize the technology of antibody production in response to future epidemic events.
KMDA Ltd. (NASDAQ and TASE: KMDA), A biopharmaceutical company specializing in plasma-based products, reports its financial results for the three months and the year ended December 31, 2020.
“We are pleased with our ability to address the operational challenges posed by the global corona epidemic and our ability to meet our 2020 major financial targets,” he said. Amir London, CEO of KamHada. “Total revenue in 2020 amounted to $ 133.2 million, in line with our annual forecast which was between $ 132 million and $ 137 million. Revenue in 2020 represents a 5% increase over revenue in 2019. These results are a result of the company’s core strengths. ”
“The acquisition of Blood and Plasma Research Inc. (B&PR)’s plasma collection center, and the establishment of its subsidiary Kamada Plasma LLC, represent our entry into the US plasma collection market and advance our strategic goal of becoming a unique vertical plasma products company. This acquisition is expected to improve our level of competitiveness. “We plan to significantly expand the antibody-rich plasma collection activity by investing in this collection center, and by leveraging the existing FDA license for this center to open additional collection centers in the United States,” Mr London continued.
“We are continuing the development and accelerated production of our experimental antibody preparation as a treatment for corona patients (COVID-19), which is provided to the Israeli Ministry of Health in an amount that is expected to be used to treat about 500 hospitalized patients, in accordance with the agreement. “We are increasing the production volume of the product using the plasma collected in the US by our partner Kadrion Biopharma, as assessments for the possibility of expanding supplies to the Israeli Ministry of Health and possible demand in other international markets,” Mr. London added.
“In addition, we continue to develop our product portfolio, focusing on the Phase 3 InnovAATe clinical trial in AAT inhalation to treat the deficiency disease with the alpha-1 antitrypsin protein, and identifying strategic business development opportunities that will leverage and expand our development, manufacturing and marketing capabilities. “In addition, we plan to utilize the technology of manufacturing our antibody preparations, in response to future epidemic events,” concluded Mr. Amir London.
As we have previously reported, the transition of Galicia to Tacada, and the continued business uncertainty resulting from the continuation of the global corona epidemic are expected to reduce our total and profitable revenues in 2021. At the same time, Kamahada continues to focus on expanding its existing growth engines including:
• Continued growth in the US market share of the anti-rabies antibody preparation (KedRAb).
• Increase in sales of Galicia and antibody preparations in international markets outside the US, including registration and launch of products in new international markets.
• Royalties are expected from Galicia sales in the U.S. estimated at between $ 10 million and $ 20 million per year, starting in 2022.
• Launch of a portfolio of nine biosimilar products for distribution in Israel between 2022 and 2025, following regulatory approval, and whose maximum total revenue from their sale is expected to be between $ 25 million and $ 35 million.
• Utilization of the manufacturing facility and the company’s experience in providing manufacturing services for unique antibody preparations, including an FDA-approved antibody preparation marketed in the US which is expected to add about $ 8 million to $ 10 million to Kamhada’s annual revenue, starting in 2023.
Financial highlights regarding the three months ended December 31, 2020
• Total revenue totaled $ 31.5 million in the fourth quarter of 2020, down 2% from $ 32.1 million recorded in the fourth quarter of 2019.
• Gross profit was $ 10.2 million in the fourth quarter of 2020, compared to $ 12.1 million reported in the fourth quarter of 2019.
• Net income was $ 1.6 million, or $ 0.04 per share, in the fourth quarter of 2020, compared to net income of $ 5.4 million, or $ 0.13 per share, in the fourth quarter of 2019.
Adjusted EBITDA, as detailed in the table below, was $ 4.0 million in the fourth quarter of 2020, compared to $ 6.8 million in the fourth quarter of 2019.
• Cash flow from operating activities was $ 12.4 million in the fourth quarter of 2020, compared to cash flow from operating activities of $ 8.6 million in the fourth quarter of 2019.
Financial highlights regarding the year ended December 31, 2019
• Total revenue amounted to $ 133.2 million in the year ended December 31, 2020, an increase of 5% from $ 127.2 million recorded in 2019
• Gross profit was $ 47.6 million in the year ended December 31, 2020, compared to $ 49.7 million reported in 2019.
• The gross profit margin from the manufacturing sector was 43% in the year ended December 31, 2020, a decrease of 3% from the corresponding period in 2019. This decrease is in line with the company’s forecast for an overall decline in the gross margin of the industrial products segment of three to five percent, compared to 2019. .
• Operating expenses, including research and development expenses, selling and marketing expenses, management and general expenses, amounted to $ 28.3 million in the year ended December 31, 2020, compared to $ 27.0 million in the year ended December 31, 2019.
• The 4% increase in research and development expenses between the years 2020 and 2019 was lower than the company’s forecast for an increase of about 13% to 15%. This phenomenon is mainly explained by a lower-than-planned patient recruitment rate in the Phase 3 InnovAATe Phase 3 clinical trial due to the effects of coronary heart disease.
• Net income was $ 17.1 million, or $ 0.38 per share (fully diluted), in the year ended December 31, 2020, compared to net income of $ 22.3 million, or $ 0.55 per share, in 2019.
• Adjusted EBITDA, as detailed in the table below, was $ 25.1 million in the year ended December 31, 2020, compared to $ 28.5 million in 2019.
• Cash flow from operating activities was $ 19.1 million in the year ended December 31, 2020, compared to cash flow from operating activities of $ 27.6 million in 2019.
Principles of the balance sheet
As of December 31, 2020, the Company has cash balances, cash equivalents and short-term investments of $ 109.3 million, compared to $ 73.9 million as of December 31, 2019. The increase is due to the net proceeds generated by the $ 25 million private placement signed with the Pimi Fund in February. 2020, as well as cash flow from operating activities.
Main events in the company:
• Acquisition of the Blood and Plasma Research Inc (B&PR) Plasma Collection Center, a private company from the town of Beaumont in Texas, USA, which specializes primarily in collecting antibodies rich in antibodies for the anti-D product manufactured by KamHada.
• Delivery of the plasma-based antibody preparation (IgG) as a treatment for corona patients (COVID-19) to the Israeli Ministry of Health has begun, and the supplies are expected to generate revenue of $ 3.4 million for Kama Science.
• Signing agreements with two international companies for the distribution of three biosimilar products in Israel. Subject to the approval of the products by the European Health Authority (EMA) and then by the Israeli Ministry of Health. The three products are expected to be launched in Israel between 2022 and 2024, and Kamahda estimates the maximum total sales potential from the distribution of these three products, which can be achieved after receiving regulatory approval and within a few years of launch, in the range of $ 5 million to $ 7 million per year.
The company’s stock has been added to the Nasdaq Biotechnology Equities Index (NBI), which is designed to track the performance of Nasdaq listed stocks and are defined as biotechnologies or pharmaceuticals in accordance with accepted industrial definitions.
For full reports